Drug Profile
Interferon beta-1b - Nuron Biotech
Alternative Names: BaroFeron; Interferon beta-1b - Nuron Biotech/BaroFold; NU-100; Recombinant human interferon beta - BaroFold/Nuron Biotech; RelonsivLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BaroFold
- Developer Nuron Biotech
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunomodulators; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 13 Nov 2012 Nuron Biotech completes enrolment in its phase III trial for Multiple sclerosis in Italy, Bulgaria, Hungary, Poland, Spain, Belarus, Croatia, Georgia, Serbia, Ukraine, Russia & Lebanon (NCT01464905)
- 31 Oct 2011 Phase-III clinical trials in Multiple sclerosis in Bulgaria (SC)
- 31 Oct 2011 Phase-III clinical trials in Multiple sclerosis in Croatia (SC)